In Part 4 of this Exclusive Interview, Dr. Osama Hamdy talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about how to safely fast to benefit weight loss and how to eat for maximum satiety.

In this week's Homerun Slides, a focus on empagliflozin, another therapeutic approach in the treatment of CKD in this albuminuria presentation by Dr. Claude Lardinois.

What is “metabolomics?” Metabolomics is an emerging field of analytical chemistry whose goal is to quantify all metabolites in a biologic sample, typically through application of multiple analytical platforms that enable determinations across a variety of metabolite classes. As with other omics-based technologies, this comprehensive coverage of metabolism has the benefit of allowing the observation of metabolic stressor effects not only at a single target, but also the ripple effect of the stressor, including compensatory responses, across the metabolic landscape.

This week insulin takes a front row in treating diabetes with the information on a new super rapid insulin. This insulin, discussed in this week’s item 2,  gives flexibility at meal time that has been lacking for a lot of patients. Also, as Animas leaves the insulin pump market, a …

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

A new formulation of Insulin Aspart can offer better glycemic control and may also be given after meals.

New study finds incidence of thyroid disorders in people with diabetes no higher than than those without.

Canagliflozin may reduce the risk of major cardiovascular complication, but amputation risk is increased.

Among long-term users, discontinuation of low-dose aspirin in absence of surgery or bleeding had a greater than 30% increased risk of cardiovascular events.

Insulin pumps therapy is associated with better glycemic control and fewer complications, new study suggests.